Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention

Autoimmunity Reviews

Volumn 1, Issue 1-2, 2002, Pages 55-60

  Meroni, Pier Luigi ^a   Raschi, Elena ^a   Testoni, Cinzia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti 2 glycoprotein I antibody; Anti phospholipid syndrome; Endothelium; Statin

Indexed keywords

ANTIGEN; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; EPITOPE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN FC FRAGMENT; PHOSPHOLIPID ANTIBODY; PROCOAGULANT; PROTEIN; STATIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; GLYCOPROTEIN;

ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BINDING AFFINITY; CELL ACTIVATION; CELL DAMAGE; CELL FUNCTION; CELL MEMBRANE; CIRCULATION; DRUG ACTIVITY; ENDOTHELIUM; ENDOTHELIUM CELL; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INFLAMMATION; LEUKOCYTE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; TARGET CELL; THROMBOPHILIA; UPREGULATION; VASCULITIS; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; ENDOTHELIUM, VASCULAR; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, BIOLOGICAL;

EID: 0141888084     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(01)00014-3     Document Type: Review

References (33)

1. Meroni P.L., Raschi E., Testoni C., Tincani A., Balestrieri G. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am. 27:2001;587-602.
2. McIntyre J.A. Immune recognition at the maternal-fetal interface: overview. Am J Reprod Immunol. 28:1992;127-131.
3. La Rosa L., Meroni P.L., Tincani A., et al. β2-glycoprotein I and placental anti-coagulant protein I in placentae from patients with anti-phospholipid syndrome. J Rheumatol. 21:1994;1684-1698.
4. Del Papa N., Guidali L., Sala A., et al. Endothelial cell as target for antiphospholipid antibodies. Arthritis Rheum. 40:1997;551-561.
5. Praprotnik S., Blank M., Meroni P.L., Rozman B., Eldor A., Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. Arthritis Rheum. 44:2001;1484-1494.
6. Ma K., Simantov R., Zhang J.C., Silverstein R., Hajjar K.A., McCrae K.R. High affinity binding of β2-glycoprotein I to human endothelial cells is mediated by Annexin II. J Biol Chem. 20:2000;15541-15548.
7. Del Papa N., Sheng Y.H., Raschi E., et al. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2glycoprotein I antibodies. J Immunol. 160:1998;5572-5578.
8. Cai G., Satoh T., Hoshi H. Purification and characterization of an endothelial cell-viability maintaining factor from fetal bovine serum. Biochim Biophys Acta. 1269:1995;13-18.
9. Caronti B., Calderaro C., Alessandri C., et al. Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol. 115:1999;214-219.
10. Meroni P.L., Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheumatol. 13:2001;377-382.
11. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, Khamashta MA., Tremoli E, Camera M. Statins prevent endothelial cell activation induced by anti-phospholipid (anti-β2 glycoprotein I) antibodies: effect on the pro-adhesive and pro-inflammatory phenotype. Arthritis Rheum in press 2001.
12. Del Papa N., Raschi E., Catelli L., et al. Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies. Am J Reproduc Immunol. 38:1997;212-217.
13. Nawrot P., Stern D. Endothelial cell procoagulant properties and the host response. Semin Thromb Hemost. 13:1987;391-398.
14. Amengual O., Atsumi T., Khamashta M.A., Hughes G.R. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost. 79:1998;276-281.
15. Atsumi T., Khamashta M.A., Haworth R.S., et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum. 41:1998;800-807.
16. Pierangeli S.S., Gharavi A.E., Harris E.N. Experimental thrombosis and antiphospholipid antibodies: new insights. J Autoimmun. 15:2000;241-247.
17. Pierangeli S.S., Espinola R.G., Liu X., Harris E.N. Thrombogenic effects of anti-phospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 88:2001;245-250.
18. Kaplanski G., Cacoub P., Farnarier C., et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum. 43:2000;55-64.
19. Combes V., Simon A.C., Grau G.E., et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 104:1999;93-102.
20. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 319:1988;24-33.
21. Kreuzer J., Bader J., Jahn L., Hautmann M., Kubler W., Von Hodenberg E. Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis. 90:1991;203-209.
22. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res. 83:1998;683-690.
23. Camera M., Maderna P., Gaviraghi M., Tremoli E. Fluvastatin blocks NF-κB-mediated Tissue Factor induction in human endothelial cells. Atherosclerosis. 133:1996;269.
24. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med. 6:2000;1004-1010.
25. Farmer J.A. Pleiotropic effects of statins. Curr Ather Rep. 2:2000;208-217.
26. Kimura M., Kurose I., Russell J., Granger D.N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Artherioscler Thromb Vasc Biol. 19:1997;1521-1526.
27. Hackman A., Abe Y., Insull W. Jr, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 93:1996;1334-1338.
28. Lefer A.M., Campbell B., Shin Y.K., Scalia R., Hayward R., Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 100:1999;178-184.
29. Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of c-reactive protein-mediated MCP-1 induction in human endothelial cells by anti-atherosclerosis drugs [abstract]. European atherosclerosis society: workshop on the immune system in atherosclerosis Geneve 2001.
30. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a new recognized type of immunomodulator. Nature Med. 6:2000;1399-1402.
31. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
32. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res. 83:1998;683-690.
33. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med. 6:2000;1004-1010.